Status: Not yet recruiting
Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia
This is a randomized, open-label phase 1/2a study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of AD-303A (topical formulation) and AD-3031 in male patients with androgenetic alopecia. The study aims to compare pharmacological characteristics and safety profiles to support dose selection for further clinical development.
Participants needed: 30
Trial details
Phase: Phase 1, Phase 2Age: 19-55Biological sex: MaleType: InterventionalSponsor: Moogene Medi Co., LtdUpdated: Mar 24, 2026Locations: 1
Eligibility criteria
Male participants aged 19 to 55 years. [+3]
History or presence of dermatologic conditions affecting the scalp other than an... [+2]